Can a K103N HIV strain stably overcome the wild type in the absence of non-nucleoside reverse transcriptase inhibitor selective pressure? [1]

AIDS

Volumn 19, Issue 6, 2005, Pages 633-634

  Capetti, Amedeo F ^a   Gabris, Alexandra I ^a   Drago, Lorenzo ^a   Vigevani, Gian Marco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; LOVIRIDE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; CASE REPORT; FEMALE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LEUKOCYTE COUNT; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; TREATMENT OUTCOME; VIRUS LOAD; VIRUS RESISTANCE;

EID: 17444380028     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000163943.31682.c8     Document Type: Letter

References (6)

1. Frost SD, Nijhuis M, Schuurman R, Boucher CA, Brown AJ. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol 2000; 74:6262-6268.
2. Japour AJ, Welles S, D'Aquila RT, Johnson VA, Richman DD, Coombs RW, et al. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J Infect Dis 1995; 171:1172-1179.
3. Albert J, Wahlberg J, Lundeberg J, Cox S, Sandstrom E, Wahren B, Uhlen M. Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in post-treatment sera. J Virol 1992; 66:5627-5630.
4. Miller V, de Bethune MP, Kober A, Sturmer M, Hertogs K, Pauwels R, et al. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Antimicrob Agents Chemother 1998; 42:3123-3129.
5. Joly V, Descamps D, Peytavin G, Touati F, Mentre F, Duval X, et al. Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs. Antimicrob Agents Chemother 2004; 48:172-175.
6. Eshelman SH, Guay LA, Mwatha A, Brown ER, Cunningham SP, Musoke P, et al. Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Defic Syndr 2004; 35:126-130.